Your single source solution for HIV diagnostics
Laboratory testing plays a vital role in the spectrum of clinical care possibilities for HIV. Labcorp is committed to providing the essential tools for clinicians to prevent, screen, diagnose, and manage HIV infections.
Explore HIV Capabilities
HIV Screening and Diagnosis
HIV Drug Resistance Testing
Pre-Exposure Prophylaxis (PrEP) Profiles
Delivering Critical Insights
at Every Step of Patient Care
Our testing gives you both flexibility and reliability. Labcorp offers dedicated HIV client services and a national infrastructure of more than 2,000 patient service centers. Connectivity solutions range from easy-to-use web based applications to sophisticated integrations that allow efficient and effective communication.
View all HIV test codes
-
Pre-exposure prophylaxis (PrEP)
We offer the latest CDC-recommended PrEP baseline and monitoring panels for oral and injectable PrEP, helping you minimize unnecessary out-of-pocket costs so you can focus on what matters most: your patients.
PrEP Testing Capabilities
-
Testing options for screening and diagnosis
The Centers for Disease Control (CDC) recommends HIV testing for all individuals between ages 13 and 64 at least once as part of standard health care.
Annual screening is recommended for those persons with known or reported risk factors. All pregnant persons should be tested for HIV.
HIV Screening and Diagnosis
Test options include HIV testing options include:
HIV p24 antigen/antibody with reflex to confirmation (083935)
HIV-1, HIV-2 qualitative RNA (139825)
HIV-1 quantitative RNA (550430)
-
Testing for patients who are newly diagnosed, treatment naïve or experiencing 1st or 2nd therapy failure
The Department of Health and Human Services (DHHS) Guidelines recommend genotypic testing at baseline and at first and second treatment failures in patients with suboptimal response or virologic failure.1
Genotypic Testing Capabilities
Testing options include:
GenoSure PRIme®
GenoSure® Archive
GenoSure® MG
GenoSure® Integrase
-
Treatment-experienced patients with a known or suspected complex drug resistance
Labcorp provides genotypic and phenotypic testing for treatment experienced patients. Labcorp is the only laboratory offering phenotypic testing and combined genotypic-phenotypic testing to determine ARV susceptibility for complex patient scenarios.
Drug Resistance Testing
Testing options include:
PhenoSense®
PhenoSense® GT
PhenoSense® GT Plus integrase and Trofile®
-
Testing to support suppression management
Genotypic testing interrogating the viral archive along with tropism testing of the DNA compartment provide data to support treatment changes without treatment interruption.
Suppression Management Capabilities
Testing options include:
GenoSure Archive®
Trofile® DNA
- 01Pre-Exposure
- 02Screening and Diagnosis
- 03Newly Diagnosed
- 04Treatment-Experienced
- 05Virologically Suppressed
Pre-exposure prophylaxis (PrEP)
We offer the latest CDC-recommended PrEP baseline and monitoring panels for oral and injectable PrEP, helping you minimize unnecessary out-of-pocket costs so you can focus on what matters most: your patients.
PrEP Testing Capabilities
Testing options for screening and diagnosis
The Centers for Disease Control (CDC) recommends HIV testing for all individuals between ages 13 and 64 at least once as part of standard health care.
Annual screening is recommended for those persons with known or reported risk factors. All pregnant persons should be tested for HIV.
HIV Screening and Diagnosis
Test options include HIV testing options include:
HIV p24 antigen/antibody with reflex to confirmation (083935)
HIV-1, HIV-2 qualitative RNA (139825)
HIV-1 quantitative RNA (550430)
Testing for patients who are newly diagnosed, treatment naïve or experiencing 1st or 2nd therapy failure
The Department of Health and Human Services (DHHS) Guidelines recommend genotypic testing at baseline and at first and second treatment failures in patients with suboptimal response or virologic failure.1
Genotypic Testing Capabilities
Testing options include:
GenoSure PRIme®
GenoSure® Archive
GenoSure® MG
GenoSure® Integrase
Treatment-experienced patients with a known or suspected complex drug resistance
Labcorp provides genotypic and phenotypic testing for treatment experienced patients. Labcorp is the only laboratory offering phenotypic testing and combined genotypic-phenotypic testing to determine ARV susceptibility for complex patient scenarios.
Drug Resistance Testing
Testing options include:
PhenoSense®
PhenoSense® GT
PhenoSense® GT Plus integrase and Trofile®
Testing to support suppression management
Genotypic testing interrogating the viral archive along with tropism testing of the DNA compartment provide data to support treatment changes without treatment interruption.
Suppression Management Capabilities
Testing options include:
GenoSure Archive®
Trofile® DNA
We are an acknowledged world leader
in HIV resistance and tropism testing
Unsurpassed Scientific Expertise
- Labcorp brings an unrivaled level of scientific expertise to HIV diagnostics.
- Our highly qualified team includes elite scientists and experienced HIV specialists, all committed to advancing patient care via individualized HIV-1 treatments.
- Labcorp’s experienced medical affairs professionals are available for consultations and educational programs.
History of vision and innovation
- Labcorp was an early pioneer in polymerase chain reaction (PCR) technology and molecular diagnostics for HIV.
- Labcorp has had a role in nearly every new HIV drug development since the early 1990s.
- Labcorp has ongoing collaborations with leading pharmaceutical companies to help bring next-generation therapeutic innovations to market.
Reference
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf . Accessed June 26, 2023
